Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative


Grasso G., Sfacteria A., Erbayraktar S., Passalacqua M., Meli F., Gokmen N., ...More

JOURNAL OF NEUROSURGERY-SPINE, vol.4, no.4, pp.310-318, 2006 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 4 Issue: 4
  • Publication Date: 2006
  • Doi Number: 10.3171/spi.2006.4.4.310
  • Journal Name: JOURNAL OF NEUROSURGERY-SPINE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.310-318
  • Keywords: erythropoietin, neuroprotection, spinal cord injury, rat, RECOMBINANT-HUMAN-ERYTHROPOIETIN, GLYCOGEN-SYNTHASE KINASE-3-BETA, CENTRAL-NERVOUS-SYSTEM, ATTENUATES PROGRESSIVE NECROSIS, ISCHEMIA-REPERFUSION INJURY, GLOBAL CEREBRAL-ISCHEMIA, IN-VIVO, MEDIATED NEUROPROTECTION, SUBARACHNOID HEMORRHAGE, NEUROLOGICAL RECOVERY
  • Dokuz Eylül University Affiliated: Yes

Abstract

Object. Spinal cord injury (SCI) is a devastating clinical syndrome for which no truly efficacious therapy has yet been identified. In preclinical studies, erythropoietin (EPO) and its nonerythropoietic derivatives asialoEPO and carbamylated EPO have markedly improved functional outcome when administered after compressive SCI. However, an optimum treatment paradigm is currently unknown. Because the uninjured spinal cord expresses a high density of EPO receptor (EPOR) in the basal state, signaling through these existing receptors in advance of injury (pharmacological preconditioning) might confer neuroprotection and therefore be potentially useful in situations of anticipated damage.